Review of human ibogaine research finds only three randomized trials and real cardiac risks

The question

What does the published human research actually show about ibogaine (and the related compounds noribogaine and 5-MeO-DMT) for psychiatric and substance use disorders, including how it is dosed and how safe it is?

What they did

The authors searched research databases for human studies of ibogaine, noribogaine or 5-MeO-DMT that reported clinical outcomes. They gave priority to randomized controlled trials (studies where people are assigned by chance to treatment or comparison), microdosing approaches, and sequential protocols where doses are given in stages. They then described the findings, dosing strategies and reported harms.

What they found

Only three randomized controlled trials were found. A double-blind pilot study in 20 adults with cocaine dependence reported that a single 1800 mg dose of ibogaine was associated with reduced craving compared with placebo, with follow-up of up to 24 weeks. An ascending-dose trial in 36 healthy volunteers found noribogaine at 3-60 mg was safe and well tolerated, with no opioid-like effects. A randomized crossover trial in 27 people with opioid dependence taking noribogaine 60-180 mg showed dose-dependent lengthening of the QTc interval (a heart rhythm measure linked to dangerous arrhythmias), while reductions in withdrawal symptoms were not statistically significant. Reported harms included neurologic, psychiatric and cardiac events, and deaths have occurred in people with medical and substance use conditions.

The fine print

This is a scoping review, not a pooled statistical analysis, so it describes rather than measures the overall effect. The underlying studies are very small, early-phase and short, and much of the evidence comes from case reports and observational data. Microdosing and staged dosing protocols have no standard definitions. This summary is based only on the published abstract.

What it means

Human evidence for ibogaine remains thin and comes mostly from small or uncontrolled studies, while the cardiac risks are well documented; the authors conclude that clinical use cannot be recommended until larger, well-controlled trials are done.

Evidence grade: Low. A scoping review that summarizes a small body of evidence made up mostly of case reports, observational data and three small early-phase trials, without pooling results statistically.

This summary is based on the study’s published abstract.